



**Figure S1**



**Figure S1. SREBP signaling is required for intraorgan communication from *Reverb*-hDKO hepatocytes. (A)** UMAP plots displaying the expression of representative marker genes. **(B)** Pathways that were enriched ( $p < 0.01$ ) in differentially expressed transcripts from hepatic stellate cells upon *Reverb*-hDKO. **(C)** Percentage of indicated cells in livers from 4-week HFHSD-fed control, *Reverb*-hDKO, and *Reverb/Scap*-hTKO mice. **(D)** UMAP visualization of cell clusters in livers from 4-week high fat high sucrose-fed *Reverb/Scap*-hTKO mice. **(E)** Body weight of each genetic model before and after 4-week HFHSD-feeding ( $n = 4-5$ ).

# Figure S2



**Figure S2. SREBP signaling is required for the rhythmic transcriptomic remodeling in LM upon *Reverb*-hDKO.** (A) Hepatic TG measurements in HFHS-fed control, *Reverb*-hDKO, and *Reverb/Scap*-hTKO livers. Data are presented as mean  $\pm$ SEM. (n = 3-4 per time point). (B and C) Pathways that were enriched (p < 0.01) in rhythmic transcripts dependent on hepatocytic REV-ERB (B) and enhanced rhythmic transcripts upon *Reverb*-hDKO dependent on SCAP (C). (D) Phase analysis of rhythmic transcripts in hepatocytes or LMs dependent on hepatocytic REV-ERB (E) Phase analysis of enhanced rhythmic transcripts upon *Reverb*-hDKO dependent on SCAP. (F) Relative expression of *Srebp2*, *Hmgcr*, and *Insig2* in hepatocytes. Data are presented as mean  $\pm$ SEM. (n = 3 per time point). (G) Genome browser tracks of the *Insig2* gene body and enhancer locus highlighting ChIP-seq data (PMID: 26044300) using anti-REVERB $\alpha$  antibody.



# Figure S4





Figure S4. Ligands from hepatocytes reprogram REV-ERB-dependent oscillating enhancers in LMs. (A and B) Heatmap (A) and IMAGE analysis (B) of enhanced rhythmic enhancers in LM upon hepatocytic REV-ERB disruption dependent on SCAP. (C) Mean expression of putative target genes of ENO1 in isolated LMs from control liver. (D) Relative expression of *Eno1* of LMs in livers from 4-week high fat high sucrose-fed control, *Reverb*-hDKO, and *Reverb/Scap*-hTKO mice. Data are presented as mean  $\pm$  SEM. (n = 3 per time point). (E) Ligand-receptor pair analysis. Circle plots showing links between predicted ligands from hepatocytes (tomato) with their associated receptors from LM (blue) associated with rhythmic transcripts in LM dependent on hepatocytic REV-ERB potentially targeted by the ligand-receptors pairs. (F) PDGFD protein levels in control and *Reverb*-hDKO livers. (G) Relative expression of *Bmp5* in hepatocytes and *Bmpr1a* in LMs. Data are presented as mean  $\pm$  SEM. (n = 3 per time point). (H) TF binding similarity screening on rhythm enhanced transcript upon *Reverb*-hDKO and dependent of SCAP. (I) Percentages of SCAP-independent and SCAP-dependent rhythmic genes in *Reverb*-hDKO whose gene body genomic locus contains REV-ERB binding sites.

**Figure S5**



**Figure S5. LM diurnal rhythms controlled by SCAP-dependent lipid metabolism in REV-ERB-depleted hepatocytes.** Heatmap of rhythmic lipids in hepatocytes upon hepatocytic REV-ERB disruption independent and dependent on SCAP. PI, phosphatidylinositol; PG phosphatidylglycerol; CL, cardiolipin; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, phosphatidylserine; DAG, diacylglycerol; TAG, triacylglycerol. The rhythms of lipids independent on SCAP upon hepatocytic REV-ERB disruption were labeled as purple, and SCAP-dependent lipids were labeled as violet. The lipids whose abundance was increased upon hepatocytic REV-ERB disruption have a light-green background, and the lipids with decreased abundance have a light-yellow background.